Home Cart Sign in  
Chemical Structure| 73030-71-4 Chemical Structure| 73030-71-4

Structure of Atractylenolide III
CAS No.: 73030-71-4

Chemical Structure| 73030-71-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Atractylenolide III, a natural product isolated and purified from the rhizome of Atractylodes macrocephala Koidz., may have therapeutic potential in treating homocysteine-mediated cognitive impairment and neuronal injury, and is a potential candidate for treatment of human lung carcinoma by inducing the release of cytochrome c, upregulating the expression of bax and translocating apoptosis-inducing factor.

Synonyms: ICodonolactone; 8β-Hydroxyasterolide; Codonolactone

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Atractylenolide III

CAS No. :73030-71-4
Formula : C15H20O3
M.W : 248.32
SMILES Code : O=C1C(C)=C(C[C@@]23[H])[C@@](C[C@@]3(C)CCCC2=C)(O)O1
Synonyms :
ICodonolactone; 8β-Hydroxyasterolide; Codonolactone
MDL No. :MFCD00238543
InChI Key :FBMORZZOJSDNRQ-GLQYFDAESA-N
Pubchem ID :155948

Safety of Atractylenolide III

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Isoform Comparison

Biological Activity

Description
Atractylenolide III, also known as ICodonolactone, constitutes the primary active compound of the Atractylodes rhizome and exhibits the capability to induce apoptosis in lung cancer cells. It is recognized for its oral efficacy as a gastroprotective agent .

In Vitro:

Cell Line
Concentration Treated Time Description References
HepG2 cells 12.5, 25, 50 µg/ml 24 h To evaluate the effects of ATL III on lipid metabolism, ATL III treatment significantly reduced FFAs-induced lipid accumulation in HepG2 cells. Int J Biol Sci. 2022 Jan 31;18(4):1594-1611
bEnd.3 cells 10 µM 2 h To evaluate the effect of Atractylenolide III combined with Atractylenolide I and Paeoniflorin on the tube formation of bEnd.3 cells. The results showed that the combination significantly promoted cell tube formation. Chin Med. 2024 Jan 4;19(1):3
bEnd.3 cells 10 µM 16 h To evaluate the effect of Atractylenolide III combined with Paeoniflorin on the migration of bEnd.3 cells. The results showed that the combination significantly promoted cell migration. Chin Med. 2024 Jan 4;19(1):3
bEnd.3 cells 10 µM 24 h To evaluate the effect of Atractylenolide III combined with Atractylenolide I and Paeoniflorin on the proliferation of bEnd.3 cells. The results showed that the combination significantly promoted cell proliferation. Chin Med. 2024 Jan 4;19(1):3
Rat HSC cell line T6 20, 30 or 40 mM Atractylenolide III inhibits ASCT2 expression, induces HSC senescence, and reduces proinflammatory SASP production Acta Pharm Sin B. 2022 Sep;12(9):3618-3638

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6J mice HFD-induced NAFLD model Tail intravenous injection 10 mg/kg Every other day for 4 weeks ATL III treatment significantly ameliorated liver injury and hepatic lipid accumulation in the HFD-induced NAFLD mouse model, reducing serum levels of ALT, AST, TG, TC, and LDL. Int J Biol Sci. 2022 Jan 31;18(4):1594-1611
ICR mice CCl4-induced liver fibrosis model Intraperitoneal injection 20, 30 or 40 mg/kg Three times a week for 8 weeks Atractylenolide III induces HSC senescence by inhibiting ASCT2 and ameliorates liver fibrosis Acta Pharm Sin B. 2022 Sep;12(9):3618-3638

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.03mL

0.81mL

0.40mL

20.14mL

4.03mL

2.01mL

40.27mL

8.05mL

4.03mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories